Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
+1.15%-2.81%+53.73%+71.00% 65.56B
-2.42%-0.90%+8.08%+89.34% 60.41B
-1.03%+0.42%+23.06%+86.99% 55.76B
-0.76%-3.57%+8.56%+118.79% 46.98B
-2.20%-5.75%+20.00%+26.64% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-2.68%-15.70%+135.38%+662.99% 36.09B
-0.77%-2.26%+77.17%+57.87% 32.9B
-2.90%-0.13%-39.54%+380.82% 26.96B
Average -1.15%-1.71%+33.39%+171.07% 45B
Weighted average by Cap. -1.13%-1.48%+33.20%+146.68%
Logo ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
Employees
56
  1. Stock Market
  2. Stocks
  3. ARYX Stock